Efg Asset Management (Americas) Corp. Seagen Inc. Transaction History

Efg Asset Management (Americas) Corp.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	SELL	$127.59 - $203.08 $857,277 - $1.36 Million	-6,719 Reduced 25.14%	20,006 $4.05 Million
Q4 2022 Feb 09, 2023	BUY	$117.37 - $139.17 $121,712 - $144,319	1,037 Added 4.04%	26,725 $3.43 Million
Q3 2022 Nov 07, 2022	SELL	$135.27 - $180.11 $585,854 - $780,056	-4,331 Reduced 14.43%	25,688 $3.52 Million
Q2 2022 Jul 13, 2022	SELL	$108.81 - $179.33 $337,637 - $556,460	-3,103 Reduced 9.37%	30,019 $5.31 Million
Q1 2022 May 05, 2022	BUY	$119.61 - $157.85 $127,863 - $168,741	1,069 Added 3.34%	33,122 $4.77 Million
Q4 2021 Jan 24, 2022	BUY	$142.57 - $190.86 $1.27 Million - $1.7 Million	8,930 Added 38.62%	32,053 $4.96 Million
Q3 2021 Oct 22, 2021	BUY	$142.45 - $169.82 $809,828 - $965,426	5,685 Added 32.6%	23,123 $3.93 Million
Q2 2021 Jul 23, 2021	BUY	$135.08 - $161.1 $1.19 Million - $1.42 Million	8,843 Added 102.89%	17,438 $2.75 Million
Q1 2021 Apr 09, 2021	BUY	$137.51 - $190.8 $979,483 - $1.36 Million	7,123 Added 483.9%	8,595 $1.19 Million
Q4 2020 Feb 05, 2021	BUY	$164.63 - $211.93 $242,335 - $311,960	1,472 New	1,472 $258,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Efg Asset Management (Americas) Corp., based on Form 13F filings with the SEC.

Stay updated on Efg Asset Management (Americas) Corp. with notifications on news.